1987 INDEX

A	ureterocolonic, July 423 ureteroileal, July 414		
11.1	ureterosigmoid, submucosal tun-		
Abdomen	nels for, July 422		
infections in diabetes, Sept. 560-	Anesthesia: for carotid endarterec-		
561	tomy, Aug. 504–505		
trauma causing biliary injury, Jan.	Aneurysm: false, of subclavian ar-		
54–55	tery, Apr. 245		
wall, fibrosarcoma of, May 309	Anorectal complications: of cancer		
Abscess	chemotherapy, Oct. 624–627		
plantar, in diabetes, Sept. 568	Antibodies: monoclonal, to surface		
subhepatic, and biliary stricture.	markers. Nov. 703–704		
benign, Jan. 56			
Adenocarcinoma (see Lung adeno-	Antigenic heterogeneity: of metas- tases, Mar. 163–167		
carcinoma)	Antigens: and burns, June 379		
Adenoma			
extraintestinal, May 306-307	Antimicrobials: empiric, Apr. 228		
tubular, May 282	Antrectomy, Dec. 774		
in Gardner's syndrome, May	distal, proposed by DeMiguel, Dec. 796		
298			
villous, May 282	mucosal, for gastric ulcer, Dec.		
Adriamycin	810-812		
effect on wound breaking	suprapyloric, in gastric ulcer, Dec. 807–810		
strength, Oct. 662			
infiltration, ulcer after, Oct. 658	Antrum		
Age: in burns, June 371	mucosal stripping operation of Kirk, Dec. 811		
Air embolism, Apr. 238–239			
Airway	with ulcer removed, Dec. 793		
established by oral route, Apr.	Anus: inflammatory lesions in leu- kemia, radiotherapy of, Oct.		
231			
involvement in lung cancer, Nov.	626		
729	Aorta		
obstruction, Apr. 229–232	rupture, contained, Apr. 246, 248		
Allograft (see Burns, allograft for, ca-	tear of, Apr. 249		
daver)	Appendicitis: complicating chemo- therapy of cancer, Oct. 629-		
Allotransplantation: islet cell, in dia-	631		
betes, Sept. 589	Arteries		
Ampulla of Vater: carcinoma of,			
May 306	carotid (see Carotid artery) coronary, disease in diabetes,		
Amputation: lower limb, in diabe-	Sept. 552–553		
tes, Sept. 576–581	femoral, atherosclerosis in diabe-		
Anastomosis	tes, Sept. 548		
in biliary stricture, benign	hepatic, for infusion with im-		
end-to-end, Jan. 29–30	plantable pump, complica-		
fixation of transanastomotic	tions of, Oct. 635–640		
tube, Jan. 35	tions of, Oct. 635-640		

incision for, Jan. 31-32

technique, Jan. 35-37

subclavian, false aneurysm of,

Арг. 245

1987 INDEX

A	ureterocolonic, July 423 ureteroileal, July 414		
11.1	ureterosigmoid, submucosal tun-		
Abdomen	nels for, July 422		
infections in diabetes, Sept. 560-	Anesthesia: for carotid endarterec-		
561	tomy, Aug. 504–505		
trauma causing biliary injury, Jan.	Aneurysm: false, of subclavian ar-		
54–55	tery, Apr. 245		
wall, fibrosarcoma of, May 309	Anorectal complications: of cancer		
Abscess	chemotherapy, Oct. 624–627		
plantar, in diabetes, Sept. 568	Antibodies: monoclonal, to surface		
subhepatic, and biliary stricture.	markers. Nov. 703–704		
benign, Jan. 56			
Adenocarcinoma (see Lung adeno-	Antigenic heterogeneity: of metas- tases, Mar. 163–167		
carcinoma)	Antigens: and burns, June 379		
Adenoma			
extraintestinal, May 306-307	Antimicrobials: empiric, Apr. 228		
tubular, May 282	Antrectomy, Dec. 774		
in Gardner's syndrome, May	distal, proposed by DeMiguel, Dec. 796		
298			
villous, May 282	mucosal, for gastric ulcer, Dec.		
Adriamycin	810-812		
effect on wound breaking	suprapyloric, in gastric ulcer, Dec. 807–810		
strength, Oct. 662			
infiltration, ulcer after, Oct. 658	Antrum		
Age: in burns, June 371	mucosal stripping operation of Kirk, Dec. 811		
Air embolism, Apr. 238–239			
Airway	with ulcer removed, Dec. 793		
established by oral route, Apr.	Anus: inflammatory lesions in leu- kemia, radiotherapy of, Oct.		
231			
involvement in lung cancer, Nov.	626		
729	Aorta		
obstruction, Apr. 229–232	rupture, contained, Apr. 246, 248		
Allograft (see Burns, allograft for, ca-	tear of, Apr. 249		
daver)	Appendicitis: complicating chemo- therapy of cancer, Oct. 629-		
Allotransplantation: islet cell, in dia-	631		
betes, Sept. 589	Arteries		
Ampulla of Vater: carcinoma of,			
May 306	carotid (see Carotid artery) coronary, disease in diabetes,		
Amputation: lower limb, in diabe-	Sept. 552–553		
tes, Sept. 576–581	femoral, atherosclerosis in diabe-		
Anastomosis	tes, Sept. 548		
in biliary stricture, benign	hepatic, for infusion with im-		
end-to-end, Jan. 29–30	plantable pump, complica-		
fixation of transanastomotic	tions of, Oct. 635–640		
tube, Jan. 35	tions of, Oct. 635-640		

incision for, Jan. 31-32

technique, Jan. 35-37

subclavian, false aneurysm of,

Арг. 245

Arteriography

biliary stricture, benign, Jan. 20 in rupture of aorta, contained, Apr. 246

Ascites: malignant, peritoneovenous shunting in, and metastases, Mar. 190

Atherosclerosis: of femoral arteries in diabetes, Sept. 548

Atony: bladder, after chemotherapy of cancer, Oct. 646

Atrophy

in biliary stricture, malignant, Feb. 79

liver, Jan. 10-12

in benign biliary stricture, Jan. 43–44

nail, in Cronkhite-Canada syndrome, May 286

Autografting: islet cell, in diabetes, Sept. 590

Autotransplantation: pancreatic, in diabetes, Sept. 589–590

R

Bacteremia: in diabetes, Sept. 563 Baillie, Matthew, Dec. 768 Barium enema: in Gardner's syndrome, May 299

Barium study: of pyloric type III gastric ulcer, Dec. 778

Bile

(See also Biliary)

duct

ischemia, Jan. 14–15 strictures (*see* Biliary strictures) duct tumors, Feb. 81–115

biliary drainage procedures in, assessment for, Feb. 87–88 bypass, left duct, Feb. 108 chemotherapy of, Feb. 112–115 common duct, mid- and low,

Feb. 116–118 diagnosis, Feb. 82–84 hilar, Feb. 81–115

intrahepatic, Feb. 81–115

intubation in, Feb. 104–108 ligamentum teres approach to,

Feb. 109-112

mortality in, Feb. 107

palliative approaches, Feb. 103– 115

postoperative care, Feb. 102– 103

radiotherapy of, Feb. 112–115 resectability, assessment of,

Feb. 84–87 resection, Feb. 89–103

resection, local, with reconstruction of biliary-enteric continuity, Feb. 94–97

resection techniques, Feb. 93– 94

treatment options, Feb. 88

Biliary

(See also Bile)

cancer causing biliary obstruction, Feb. 78

decompression, Feb. 103

drainage procedure in biliary duct tumor, Feb. 87–88

 -enteric continuity reconstruction in bile duct tumors, Feb. 94– 97

enteric repair procedures, Jan. 30-31

fibrosis, Jan. 10

fistula, Jan. 28

after cholecystectomy, Jan. 27 injuries, Jan. 12-13

abdominal trauma causing, Jan.

after operations other than cholecystectomy, Jan. 52-54

obstruction biliary cancer causing, Feb. 78 pathological effects of, Jan. 10-

operations, Jan. 52–53 strictures (see below)

tree, in emphysematous cholecystitis, Sept. 560

Biliary strictures

anatomy, Jan. 7-9

variations in, Jan. 8 atrophy in, Feb. 79

benign, Jan. 7–66

anastomosis in (see Anastomosis in biliary stricture, benign) Biliary strictures (cont.) subhepatic abscess or inflamarteriography of, Jan. 20 mation in, Jan. 56 surgical procedures, Jan. 29-51 causes, Jan. 12 treatment, Jan. 25-52 causes at Hammersmith Hospitreatment, results, Jan. 46-47. tal. Jan. 53 cholangiography of, Jan. 19-21, 48-51 drainage of, mortality in, Feb. 107 malignant, Feb. 75-127 cholelithiasis in, long-standing, clinical presentation, Feb. 79-Jan. 55-56 classification, Jan. 22-24 classification, anatomical, Jan. diagnosis, Feb. 79-81 etiology, Feb. 77-78 classification based on level of incidence. Feb. 77 strictures related to confluinfection in. Feb. 79 ence of hepatic duct. Jan. laboratory investigations. Feb. clinical presentation, Jan. 17-18 location, Feb. 75-76 diagnosis, Jan. 17-22 natural history, Feb. 77 duodenal ulcer and, Jan. 56 pathology, Feb. 75-76 after gastrectomy, Jan. 53-54 pathophysiologic effects, Feb. hepaticojejunostomy in (see 78-79 Hepaticojejunostomy) radiography of, Feb. 81 injuries recognized in early management, Jan. 7-12 postoperative period, Jan. postoperative, Jan. 13 28-29 Biological dressings: for burns, June injuries recognized at time of 360-362 operation, Jan. 25-28 Biomarkers: in lung cancer, Nov. laboratory investigations, Jan. 700-702, 703 Bladder liver atrophy/hypertrophy in, artificial, July 433 Jan. 43-44 atony after chemotherapy of can-Longmire procedure in, Jan. cer. Oct. 646 39-41 cecal, July 433-438 lymphadenitis and, granulomareservoir, colonic, pressures during filling of, July 437 tous, Jan. 56 management, preoperative, Jan. Blood 24 - 25flow morbidity in, Jan. 47-48 cerebral (see Cerebral, blood mortality in, Jan. 47-48 mucosal graft surgery in, Jan. penile, in diabetes, Sept. 555 monocytes (see Monocytes, 37 - 39pancreatitis and, chronic, Jan. blood) 57 - 58portal hypertension and, Jan. perforation complicating chemo-44-46 therapy of cancer, Oct. 619postinflammatory, Jan. 55-58 prognostic factors in, Jan. 23 preparation for sigmoid conduit radiography (see Radiography diversion, July 419-420

of biliary stricture, benign)

severity, Jan. 22-24

small

injuries, Apr. 256

at laparotomy in ovarian cancer. Oct. 642 shotgun blast to, Apr. 257 Brachyradiotherapy, Oct. 664 Bronchus: tear of, Apr. 240 Burns. June 347-397 age in. June 371 allograft for, cadaver, June 363-370 exclusions, automatic, for cadaver skin donation. June indicators for use. June 364 survival after, June 367 antigens and, B and DR HLA. **June 369** antimicrobial agents, topical, alternatives to. June 360-362 biological dressings, June 360-362 death after, causes, June 370 lung complications, June 371 debridement length of hospital stay after, June 387 survival and. June 367 energy expenditure, resting, June ethical dilemma, June 386-388 excision early, length of hospital stay, **June 387** early, mortality rate in, June early, and survival, June 367 of wound, June 362-363 hypermetabolic response to, support of, June 349-356 hypermetabolism in (in rat). June infection control by conservative methods, June 356-360 inhalation injury, June 370-384 clinical signs, June 375

management. June 347-349 of wound. June 356-360 mortality (see Mortality, burns) oxygen consumption after (in rat). June 355 resuscitation after. June 347-349 of special nature, June 385 survival characteristics in children. **June 366** debridement in. June 367 excision in, early, June 367 grafts in. June 367 length of hospital stay of, June 387 total body surface area, June 372 treatment. June 347-397 variance analysis, June 373, 374 wound management. June 356-Bypass: in bile duct tumors, Feb.

C

108

Camey procedure, July 462 Cancer biliary, causing biliary obstruction, Feb. 78 cellular diversity in, origin of, Mar. 152-154 chemotherapy in (see Chemotherapy in cancer) colon, syndrome, discrete polyps in, May 294-296 lung (see Lung cancer) metastases (see Metastases) ovaries, small bowel appearance at laparotomy in, Oct. 642 rectum, after ileoproctostomy for neoplastic polyposis, May 316 Carcinoma adenocarcinoma (see Lung adenocarcinoma)

of ampulla of Vater, May 306

giocarcinoma)

cholangiocarcinoma (see Cholan-

copy. June 375

incidence, June 371

diagnosis without bronchos-

mortality in, June 371, 375

mafenide acetate "pulse" therapy

Carcinoma (cont.)

colon, resection, "no touch" surgical techniques for, Mar. 188–189

colorectal

blood monocyte activation and, Mar. 181–182

metastatic behavior of cells in, Mar. 174–175

kidney, renal cell, studies, Mar. 175–177

lung (see Lung carcinoma) periampullary, May 303–306 renal cell, studies, Mar. 175–177

Carotid artery clamping

EEG changes during, histogram display of, Aug. 516 unilateral global suppression af-

unilateral global suppression after, Aug. 512–513

Carotid artery occlusion

EEG changes during, histogram display, Aug. 512

EEG power reduction in patients with EEG changes after, Aug. 514

Carotid artery unclamping: EEG activity after, histogram display, Aug. 515

Carotid backpressure measurement, Aug. 494–496

Carotid endarterectomy, Aug. 481– 532

anesthesia in, Aug. 504–505 cerebral artery blood velocity changes during, Aug. 500

electroencephalography during, Aug. 500-519

evoked potentials and, Aug. 500-519

monitoring during (see Monitoring, intraoperative during carotid endarterectomy) morbidity of, Aug. 482–485

mortality of, Aug. 482–485 results, current, Aug. 483

Carotid occlusion EEG from, Aug. 497 risk of cerebral ischemia after,

Aug. 511

Catheter

central venous (see Central venous catheter)

effect of catheter exchange on catheter removal for suspected sepsis, Oct. 655

second, and chemotherapy, Oct. 663–667

Cecal bladder, July 433–438 Cells (see Tumor, cells)

Central venous catheter, Oct. 653 exchange over a guide wire, Oct. 655

infectious complications, Oct. 654

removal of, reasons for, Oct. 654 Cerebral

artery blood velocity changes during carotid endarterectomy, Aug. 200

blood flow, Aug. 485–491 by anesthetic used, Aug. 498 measurement by Doppler ultrasound, Aug. 499–500

measurement by EEG, indirect, Aug. 505–506

measurement, intraoperative, Aug. 497–500

regulation, mechanisms involved, Aug. 486–487

relationship to function and ischemic injury, Aug. 485–491 risk grade and, Aug. 498

blood pressure measurement, radioactive agents for, Aug. 497–499

infarction, cerebral basis, Aug. 487–491

ischemia

cellular basis for, Aug. 487–491 degree of, duration of and recovery of electrical activity, Aug. 490

relationship to blood flow and function, Aug. 485–491 risk after carotid occlusion,

Aug. 511

protection, Aug. 491–492 vascular disease in diabetes, Sept. 553–554 Charcot's osteoarthropathy: in diabetes, Sept. 571

Chemoradiotherapy: and wound healing, Oct. 659–663

Chemosensitivity testing: in lung cancer, Nov. 702–703

Chemotherapy

of bile duct tumors, Feb. 112-115

in cancer (see below)
in lung cancer (see under Lung
cancer)

tumor cell heterogeneity and, Mar. 160-163

Chemotherapy in cancer, Oct. 613-

appendicitis and, Oct. 629–631 bladder atony and, Oct. 646 bowel perforation in, Oct. 619–623

complications

anorectal, Oct. 624–627 gastrointestinal, Oct. 614–643 genitourinary tract, Oct. 643– 647

from hepatic artery infusion with implantable pump, Oct. 635–640

lung, Oct. 647–651 surgical, Oct. 613–675

cystitis and, Oct. 643-645

enteropathy and, neutropenic, Oct. 633–634

gastrointestinal bleeding in, Oct. 615–619

gastrointestinal tract perforations secondary to, Oct. 621

ileus in, paralytic, Oct. 623–624 infiltrations, local complications, Oct. 655–657

intraperitoneal, Oct. 640–643 pancreatic toxicity in, Oct. 627– 629

recurrent cancer after, Oct. 645–646

renal toxicity and, Oct. 646–647 second cancers and, Oct. 663–667

typhlitis and, Oct. 632–633 venous access, Oct. 651–655 available access alternatives, Oct. 651–652 long-term, complications of, Oct. 652–655

Chest

flail, Apr. 232-234

trauma, severe, Apr. 240

wall invasion in lung cancer, Nov. 726–727

Children: burns, characteristics of survivors, June 366

Cholangiocarcinoma

CT of, Jan. 11

hilar

cholangiography of, Feb. 90 excision, and portal vein bifurcation, Feb. 102

hepatectomy in, Feb. 105 hepaticojejunostomy in, Feb. 114

resection including hepatic resection, Feb. 97–101

with stenosis of portal vein, Feb. 86

ultrasound of, Feb. 82

papillary, in lower bile duct, Feb. 76

quality of life after resection or bypass, Feb. 92

Cholangiography

of biliary stricture, benign, Jan. 21, 45

complex, Jan. 19

in cholangiocarcinoma hilar. Feb. 90

papillary, Feb. 76

after hepatic artery infusion, Oct. 636

Cholangitis, sclerosing

ERCP in, Feb. 84

after hepatic artery infusion, Oct. 635-637

Cholecystectomy: biliary fistula after, Jan. 27

Cholecystectomy, injuries, Jan. 13– 17

anatomical variations, Jan.

causative factors, Jan. 13

hemorrhage, Jan. 14

prevention of, Jan. 13 technical factors in, Jan. 15–17 Cholecystitis: acute and emphysematous, in diabetes, Sept. 559–560

Chung method: for high lying gastric ulcer, Dec. 820

Colitis: ulcerative, pseudopolyp of, May 278

Colon

cancer syndrome, discrete polyps in, May 294–296

carcinoma, resection, "no touch" surgical techniques for, Mar. 188–189

injuries, Apr. 257-258

polyps, May 296-303

small intestine involvement in, May 300-302

transverse, for urinary diversion, July 424–425

Colorectal (see Carcinoma, colorectal)

Computed (see Tomography, computed)

Conduit

ileal (see Ileal conduit)

pressure tracings in, comparison of open and occluded, July 430

sigmoid (see Sigmoid conduit) Continent urinary diversion, July

Coronary artery disease: in diabetes, Sept. 552–553

Cost-effectiveness: of EEG monitoring, Aug. 517–518

Cowden's syndrome, May 289-290

Cricothyroidotomy, Apr. 232 Cronkhite-Canada syndrome

hamartomatous polyps of ileum in, May 287

nail atrophy in, May 286

Cruveilhier ulcer, Dec. 769

Csendes method: for high lying gastric ulcer, Dec. 821

Cyst(s): epidermal inclusion, of leg, May 308

Cystitis: after chemotherapy of cancer, Oct. 643-645

Cytoxan, Oct. 645

Death (see Mortality)

Deloyers proximal gastrectomy, Dec. 822

Desmoid (see Tumors, desmoid) Diabetes mellitus, Sept. 541–603

atherosclerosis of femoral arteries in, Sept. 548

bacteremia in, Sept. 563

cardiovascular complications of, Sept. 546–555

cerebrovascular disease in, Sept. 553–554

cholecystitis in, acute and emphysematous, Sept. 559-560

complications of, prevention of, Sept. 593–594

coronary artery disease in, Sept. 552–553

extremity amputations in, lower, Sept. 576–581

foot disorders in, Sept. 564–581 needle embedded in sole of foot, Sept. 568

soft-tissue infection, with gas bubbles in tissues, Sept. 575

hemodialysis in, vascular access for, Sept. 554–555

infections in, Sept. 555–564 fungal, Sept. 562–563 intra-abdominal, Sept. 560–561 prevention, Sept. 564 skin, Sept. 556–559 soft-tissue, Sept. 556–559 treatment, Sept. 564

urinary tract, Sept. 561–562 insulin administration (see Insulin administration)

lin administration) ketoacidosis of, emergency sur-

gery in, Sept. 546 management, problems in, Sept. 541–542

peripheral vascular disease complicating, Sept. 547–552

pneumonia in, Sept. 563–564 surgery in, Sept. 541–603

emergency, in ketoacidosis, Sept. 546 major elective operations, Sept. 544–545
management during operation. Sept. 544–546
minor surgery, Sept. 544
risks of, Sept. 542–544
surgically correctable, Sept. 581–582

risks of, Sept. 542–544
surgically correctable, Sept. 581–
582
surgically induced, Sept. 582–583
transplantation, Sept. 583–590
islet cell allotransplantation,
Sept. 589
islet cell autografting, Sept. 590
pancreatic, Sept. 585–589
pancreatic autotransplantation,
Sept. 589–590
renal, Sept. 583–585

Diaphragm injuries of, Apr. 247–249 rupture, Apr. 252

Diathermy: in biliary stricture, benign, Jan. 32 Doppler ultrasound: in cerebral

Doppler ultrasound: in cerebral blood flow measurement, Aug. 499–500 Dressings: biological, for burns,

June 360–362 Duncan's multiple range test, June

373, 374 Duodenal polyps: in Gardner's syndrome, May 305

Duodenal ulcer: and biliary stricture, benign, Jan. 56

.

Electrical activity: recovery after ischemia, Aug. 490
Electroencephalography during carotid endarterectomy, Aug. 500–519
from carotid occlusion, Aug. 497 in cerebral blood flow measurement, indirect, Aug. 505–506 changes, with late development, necessitating shunt, Aug. 522 changes reflecting malfunctioning of shunt, Aug. 521 during hypotension, Aug. 517

intraoperative use, Aug. 506–517 monitoring, cost-effectiveness of, Aug. 517–518 physiologic basis, Aug. 500–502 spectral array display, compressed, Aug. 508–511, 512– 513 technical considerations with.

Aug. 500–502
Electron microscopy: in lung cancer

diagnosis, Nov. 696–699 Embolism: air, Apr. 238–239

Embolus: multicell, and metastases, Mar. 145

Emphysematous cholecystitis biliary tree and gallbladder in, Sept. 560

in diabetes, Sept. 559–560 Endarterectomy (see Carotid endarterectomy)

Enema: barium, in Gardner's syndrome, May 299

Enostosis: maxillary, in Gardner's syndrome, May 312 Enteropathy: neutropenic, in

chemotherapy of cancer, Oct. 633–634

ERCP: in sclerosing cholangitis, Feb. 84

Esophagus hiatal hernia, chronic gastric ulcer in, Dec. 824

injuries, Apr. 243 Evoked potentials

during carotid endarterectomy, Aug. 500–519

discussion of, Aug. 502–504 intraoperative use, Aug. 506–517

Exostosis: tibial, in Gardner's syndrome, May 311

17

Face: gunshot wound of, Apr. 230 Femoral arteries: atherosclerosis in diabetes, Sept. 548

Fibrosarcoma of abdominal wall, May 309 of mesentery, May 309 Fibrosis biliary, Jan. 10 retroperitoneal, May 309 Fistula, biliary, Jan. 28 after cholecystectomy, Jan. 27 Flail chest, Apr. 232–234 Foot (see Diabetes mellitus, foot disorders in)

"Form and Function operation:" of Holle, for type I gastric ulcer, Dec. 815

Fracture (see Pelvic fracture)
Fungal infections: in diabetes, Sept.
562–563

6

Gallbladder: in emphysematous cholecystitis, Sept. 560 Ganglioneuromatosis: mucosal, May 290 Gardner's syndrome, May 296–303

adenoma in, tubular, May 298-303 adenoma in, tubular, May 298 adenomatous change in mucosa in, May 300 associated nonneoplastic disease

associated nonneoplastic disease in families with, May 313 barium enema in, May 299 data on patients with, May 296 death cause in, May 314 duodenal polyps in, May 305 fibrous tumors in, May 309 gastric polyposis in, diffuse, May 303

lymphoid aggregate in terminal ileum in, May 302 maxillary enostosis in, May 312 neoplastic diseases in families

with, May 314 rectal polyps in, May 297 tibial exostosis in, May 311

Gastrectomy
biliary stricture after, Jan. 53–54
Deloyers proximal, Dec. 822
pylorus sparing, in gastric ulcer,
Dec. 807–810
segmental, for gastric ulcer, Dec.

segmental, for gastric ulcer, Dec. 812–815

Gastric polyposis, May 302-303

Gastric resection: distal, with or without vagotomy, Dec. 791– 799

Gastric ulcer, Dec. 767–845 adherence to pancreas, Dec. 780 benign

classification of H. Daintree Johnson, Dec. 755

type I, radiography of, Dec. 776 case review, Dec. 798

chronic, in esophageal hiatal hernia. Dec. 824

classification, Dec. 773–777 complications, Dec. 829–832 diagnosis, Dec. 786–787

etiology, Dec. 772 giant, Dec. 825–828

hemorrhage complicating, Dec. 829–830

high lying, Dec. 816–825 Chung method for, Dec. 820 Csendes method, Dec. 821 Pauchet method of manage-

ment, Dec. 818 histopathology, Dec. 779–781 historical aspects, Dec. 767–771 incidence, Dec. 771–772

likely sequence of events leading to development of, Dec. 785

location of, Dec. 777–779 anatomic, Dec. 779 malignant changes of, Dec. 781

management, medical, Dec. 787– 789 obstruction complicating Dec

obstruction complicating, Dec. 831–832

parietal cell and, Dec. 805 pathogenesis, Dec. 781–785 perforation complicating, Dec. 830–831

resection, segmental, various types performed over the years, Dec. 814

signs and symptoms, presenting, Dec. 797

surgery for, Dec. 791–815 indications for, Dec. 789–791 type I, antrectomy for, distal, Dec. 796

type II, radiography of, Dec. 777

type III pyloric, barium study of, Dec. 778

pyloric channel, Dec. 792

Gastric vagotomy

proximal, for gastric ulcer, Dec. 801–807

selective, with pyloroplasty for gastric ulcer, Dec. 799–801 Gastrointestinal

bleeding in cancer chemotherapy, Oct. 615–619

complications of chemotherapy of cancer, Oct. 614–643

polyposis (see Polyposis, gastrointestinal)

tract perforation complicating chemotherapy, Oct. 621

Genitalia: trauma to, Apr. 258–259 Genitourinary tract complications: of cancer chemotherapy, Oct. 643–647

Gilchrist procedure, July 433 Graft

allograft in burns (see Burns, allograft in)

mucosal, for surgery in benign biliary stricture, Jan. 37–39

Gunshot wounds, Apr. 245 face, Apr. 230

.

Hallux valgus: and neuropathy in diabetes, Sept. 567 Hamartoma, May 277–280 Healing: wound, and chemoradiotherapy, Oct. 659–663

Heart

complications in diabetes, Sept. 546-555

injuries, Apr. 237-238

Heel: neuropathic ulcer of, Sept. 569 Hematogenous-lymphatic spread: of metastases, Mar. 141

Hemodialysis: vascular access in diabetes, Sept. 554–555

Hemorrhage

after cholecystectomy, Jan. 14 gastric ulcer complicated by, Dec. 829–830 gastrointestinal in cancer chemotherapy, Oct. 615-619

Hemothorax: massive, Apr. 236 Hendren's technique: of intussusception, July 436

Hepatectomy: in hilar cholangiocarcinoma, Feb. 105

Hepatic artery: infusion with implantable pump, complications of, Oct. 635-640

Hepaticojejunostomy, Jan. 32–35 initial steps, Jan. 37 right-sided intrahepatic, Jan. 42–

segment II, Jan. 42 segment III, Jan. 42 in cholangiocarcinoma, hilar, Feb. 114

Hernia: esophageal hiatal, chronic gastric ulcer in, Dec. 824

Hilar plate: lowering, Jan. 34

Holle's "Form and Function operation:" for type I gastric ulcer, Dec. 815

Hypermetabolism: in burns (in rat), June 354

Hyperplasia: of rectum, nodular lymphoid, May 279

Hyperplastic polyps, May 277 unclassified, May 275–276 Hypertension: portal, and benign

biliary stricture, Jan. 44–46 Hypertrophy: of liver in benign bili-

ary stricture, Jan. 43–44 Hypotension: EEG changes during, Aug. 517

.

lleal conduit diversion, July 407–418 operative technique, July 411–415 preparation of patient, July 408– 411

stoma, preparation of, July 415–418

Ileal loop diversion

Bricker's method for, July 408 Leadbetter's technique for, July

stoma, correct placement, July 410

Ileal nipple valve: intussuscepted, July 435

Ileal reservoir, July 438–464 alternatives in reservoir construction, July 457–459

formation of, July 444–451 operative technique, July 442–455 patient selection for, July 438–442 postoperative complications, July 456–457

preoperative preparation, July 442 pressures during filling, July 439– 440

results, July 455-456

lleocecal diversion, July 426–427 cutaneous, July 424

lleoproctostomy for polyposis coli, follow-up, May 318 neoplastic, rectal cancer after, May 316

Ileostomy: ureterocecocutaneous, July 433–438

Ileum

hamartomatous polyps of, in Cronkhite-Canada syndrome, May 287

suitable segment selection in ileal loop diversion, July 412–413

Ileus: paralytic, complicating chemotherapy of cancer, Oct. 623–624

Immunogenic heterogeneity: of metastases, Mar. 163–167

Immunomodulators, liposome containing

to activate macrophages, Mar. 179–181

in melanoma metastases (in mice), Mar. 183–184

Immunoperoxidase staining: in lung cancer diagnosis, Nov. 696–699

Immunotherapy: in lung cancer, Nov. 739–740

Implantable pump

for hepatic artery infusion, complications of, Oct. 635–640 for insulin administration, Sept. 592–593

Inclusion cysts: of leg, May 308

Infarction: cerebral, cellular basis of. Aug. 487–491

Inhalation injury (see Burns, inhalation injury)

Insulin administration, Sept. 591–593

pumps for, Sept. 591–593 implantable, Sept. 592–593 portable, Sept. 591–592

Intestine

(See also Gastrointestinal) polyposis, syndromes of, May 275–340

polyps, benign, histologic classification, May 276

small, involvement in colon polyps, May 300-302

ureterointestinal diversion, complications of, July 425-431

Intraoperative (see Monitoring, intraoperative)

Intubation

in bile duct tumors, Feb. 104–108 nasotracheal, attempted, Apr. 231 Intussuscepted ileal nipple valve,

July 435 Intussusception: Hendren's technique for, July 436

Ischemia

bile duct, Jan. 14–15 cerebral (see Cerebral, ischemia)

Islet cell allotransplantation: in diabetes, Sept. 589

Islet cell autografting: in diabetes, Sept. 590

.

Jejunal loop: in biliary stricture surgery, benign, Jan. 38 Johnson, H. Daintree, Dec. 774

K

Kelling/Madlener operation: modification of, Dec. 817 Ketoacidosis: diabetic, emergency

Ketoacidosis: diabetic, emerger surgery in, Sept. 546

Kidnev

injury, CT of, Apr. 260

toxicity and chemotherapy of cancer, Oct. 646-647

transplant in diabetes, Sept. 583– 585

Kirk antral mucosal stripping operation, Dec. 811

Kock pouch (see Ileal reservoir)

.

Lasers (see Lung cancer, lasers for) Leadbetter's technique: for ileal loop diversion, July 409 Leg: epidermal inclusion cysts of,

May 308

Leukemia: perianal inflammatory lesions in, radiotherapy of, Oct. 626

Ligament: round, for approach to bile duct tumors, Feb. 109– 112

Ligamentum teres approach: to bile duct tumors, Feb. 109–112

Liposome

-activated blood monocytes, Mar. 180, 182

containing immunomodulators to activate macrophages, Mar. 179–181

for melanoma metastases (in mice), 183–184

Liver

anatomy, segmental, Jan. 9 atrophy, Jan. 10–12

benign biliary stricture and, Jan. 43–44

bridge of tissue at umbilical fissure base in bile duct tumor resection. Feb. 95

hilus, exposure of structures, Feb.

hypertrophy in benign biliary stricture, Jan. 43–44

injuries of, Apr. 252–254 intraparenchymal injury, CT of, Apr. 253

resection

in bile duct tumors, Feb. 97– 101 with excision of bifurcation of portal vein, Feb. 101–103 Lobectomy: right hepatic, Feb. 104 Longmire procedure: in jejunal

stricture, benign, Jan. 39-41

Lung adenocarcinoma

bronchioloalveolar subtype, Nov. 693–694

moderately differentiated, Nov. 693

mucus lake, Nov. 697

pathology, Nov. 692-694

Lung cancer, Nov. 687-758

airway involvement in, Nov. 729 biology of, Nov. 699–704

biomarkers in, Nov. 700–702, 703 chemosensitivity testing in, Nov. 702–703

chest wall invasion in, Nov. 726-

classification of WHO, 689 diagnosis

electron microscopy in, Nov. 696–699

immunoperoxidase staining, Nov. 696–699

diagnostic evaluation, Nov. 708– 721

endobronchial lesion, obstruction of, palliation of, Nov. 741–742

immunotherapy in, Nov. 739-740 incidence data

Johns Hopkins University, Nov. 706

Mayo Clinic, Nov. 706

Memorial Sloan-Kettering Cancer Center, Nov. 707–708

lasers for, Nov. 740-744

laser systems, Nov. 742–744 technique, Nov. 742–744

lymph node mapping, Nov. 719– 721

M₁ disease and, Nov. 730 mediastinal invasion in, Nov. 728-

mediastinal node assessment, preoperative, Nov. 716–718

mixed type, unifying hypothesis for, Nov. 701 Lung cancer (cont.) treatment, Nov. 722-740 monoclonal antibodies to surface Lung carcinoma markers in. Nov. 703-704 adenosquamous, pathology, Nov. N₂ tumors and, Nov. 730 695-696 non-small-cell early localized chemotherapy of, Nov. 733-734 diagnosis, Nov. 740-741 combination radiotherapy. treatment, Nov. 740-741 chemotherapy and surgery. large-cell Nov. 734-736 pathology, Nov. 694-695 radiotherapy, Nov. 731-733 undifferentiated cells. Nov. radiotherapy, curative, Nov. 699 oat cell type, Nov. 691 radiotherapy, palliative, Nov. small-cell 733 cell size. Nov. 691 radiotherapy, postoperative adneurosecretory granules, Nov. iuvant, Nov. 732-733 radiotherapy, preoperative adpathology, Nov. 691-692 juvant, Nov. 731-732 squamous cell surgery of, Nov. 722-730 moderately differentiated, Nov. occupational factors contributing to development of, Nov. 688 pathology, Nov. 690-691 oncogenes in, Nov. 700 Lung complications Pancoast tumors and, Nov. 727in burns. June 371 in chemotherapy of cancer, Oct. pathology, Nov. 688-699 647-651 prevalence data results, Nov. 705clinical features, Oct. 650 diagnoses, pathologic and miresection crobiologic, Oct. 650 laboratory findings, Oct. 649 lower lobe sleeve, Nov. 726 segmental, types of, Nov. 722-Lung contusion, Apr. 240, 241-243 CT of, Apr. 241, 242 upper lobe sleeve, Nov. 724-725 Lymph nodes results, end, American Joint Combarrier function in metastases. mittee on Cancer, Nov. 709, Mar. 142-144 710, 714 dissection for micrometastases, screening for, Nov. 704-708 Mar. 184-185 small-cell mapping, Nov. 719-721 chemotherapy of, Nov. 737-738 pulmonary nodes, regional, map radiotherapy, Nov. 738 of, Nov. 720 surgery of, Nov. 738-739 sites of, Nov. 717 treatment, Nov. 736-737 stations, regional, definitions of, staging, Nov. 708-721 Nov. 721 American Joint Committee on Lymphadenitis: granulomatous, and Cancer, Nov. 709, 710, 714 benign biliary stricture, Jan. International System, Nov. 714 New International System, Nov. Lymphatic-hematogenous spread: 712, 713 of metastases, Mar. 141 surgeon's approach, Nov. 687-758 Lymphatic spread: of metastases,

survival. Nov. 727, 729

Mar. 141-142

M₁ disease: and lung cancer, Nov. 730

Macrophage

activation by liposomes containing immunomodulators, Mar. 179–181

antimicrobial properties, activation of Mar. 178–179

antitumor properties, activation of, Mar. 178–179

physiological role, Mar. 177-178

systemically activated, in treatment of micrometastases, Mar. 177–184

Mafenide acetate "pulse" therapy: of burns, June 358

MAINZ pouch, July 458

Maki, T., Dec. 808

Malignancy (see Cancer)

Mal perforans ulcer: in diabetes, Sept. 567

Maxillary enostosis: in Gardner's syndrome, May 312

Mediastinal

invasion in lung cancer, Nov. 728–729

node assessment: preoperative, Nov. 716–718

Mediastinoscopy: major anatomical structures identified at, Nov. 718

Melanoma

allogeneic, Mar. 180

growth, intravascular (in mice), Mar. 147

metastases (see Metastases, melanoma)

variants with increased metastases, successive selection of, Mar. 149

Mesentery: fibrosarcoma of, May 309

Metastases, Mar. 137-209

in ascites, malignant, after peritoneovenous shunting, Mar. 190 biology of, Mar. 137–209 nude mice to study, Mar. 171–177

cells

biologic behavior of, host microenvironment in, Mar. 170–171

selection for, in vitro, Mar. 150

in colorectal carcinoma, Mar. 174–175

embolus in, multicell, Mar. 145 excising to prevent further dissemination, Mar. 189–190

formation of, Mar. 138

heterogeneity

antigenic, Mar. 163-167

biologic, Mar. 146-159

biologic, challenge of, Mar. 159–167

biologic, origin of, Mar. 156–157 experiment in, design of, Mar. 151

imreunogenic, Mar. 163–167 intralesional, development of, Mar. 157–159

of tumor cells in primary neoplasms, Mar. 148-152

heterogeneous tumor populations, instability of, Mar. 154–156

host organ environment in, Mar. 169–170

invasion, Mar. 138-141

lymph nodes in, barrier function of, Mar. 142–144

of melanoma

design of experiment demonstrating, Mar. 158

liposome containing, immunomodulators for (in mice), Mar. 183–184

metastatic behavior of tumor cells, Mar. 174-175

micrometastases

lymph node dissection in, Mar. 184–186

systemically activated macrophages, Mar. 177-184 Metastases (cont.)

microscopic, risk determination in surgical patients, Mar. 187–188

pathogenesis, Mar. 138–146 patterns of, Mar. 167–171

propensity of human tumor cells (in nude mice), Mar. 173–174

resection, selection of patients for, Mar. 186–187

selection of variant cells with increased properties for metastases, Mar. 149

spread

hematogenous, Mar. 144–146 lymphatic, Mar. 141–142 lymphatic-hematogenous, Mar. 141

surgery of

practical considerations in, Mar. 184–190

"urgent," is there a justification for? Mar. 186

therapy of, nude mice to study, Mar. 171-177

Micrometastases (see Metastases, micrometastases)

Microscopy: electron, in lung cancer diagnosis, Nov. 696–699

Monitoring: EEG, cost-effectiveness of, Aug. 517–518

Monitoring, intraoperative, during carotid endarterectomy, Aug. 481–532

carotid backpressure measurement, Aug. 494–496

developing techniques, Aug. 518–519

direct observation, Aug. 492–494 neurologic, Aug. 492–519 "stump pressure" measurement, Aug. 494–496

Monitoring, intraoperative: clinical integration of, Aug. 519–523

Monitoring, intraoperative: rationale for, Aug. 482

Monoclonal antibodies: to surface markers in lung cancer, Nov. 703–704 Monocytes

blood

activation in colorectal carcinoma, Mar. 181-182

liposome-activated, Mar. 180, 182

tumoricidal, interaction with heterogenous neoplasms, Mar. 181

Morbidity

of carotid endarterectomy, Aug. 482-485

operative, in benign biliary stricture, Jan. 47-48

Mortality

in bile duct tumors, Feb. 107

causes of death, June 370 after early excision, June 368 inhalation injury and, June 371, 375

inhalation injury causing, June 371

study of, June 386

of carotid endarterectomy, Aug. 482–485

cause in Gardner's syndrome, May 314

operative, in biliary stricture, benign, Jan. 47–48

Motor vehicle accidents: torso injury in, incidence, Apr. 220

Mucosal antrectomy: for gastric ulcer, Dec. 810–812

Mucosal ganglioneuromatosis, May 290

Mucosal graft surgery: in benign biliary strictures, Jan. 37–39 Myocardium: contusion, Apr.

243–244

N

N₂ tumors: and lung cancer, Nov. 730

Nail atrophy: in Cronkhite-Canada syndrome, May 286

Nasotracheal intubation: attempted, Apr. 231

Neoplasms (see Tumors)

Neoplastic polyposis (see Polyposis, neoplastic)

Neoplastic polyps, May 280–283 Neuropathy: in diabetes complicated by hallux valgus and ulcer, Sept. 567

Neutropenic enteropathy: complicating chemotherapy of cancer, Oct. 633–634

"Nipple"

intussuscepted ileal nipple valve, July 435

protruding, in stoma construction, July 417

Norman Tanner Rotation Maneuver, Dec. 819

n

Oncogenes: in lung cancer, Nov. 700 Organs: "apparent weight," in violent impact, Apr. 220

Osteoarthropathy: Charcot's, in diabetes, Sept. 571

Ovarian cancer: small bowel appearance at laparotomy in, Oct. 642

Oxygen consumption: after burns (in rat), June 355

p

Pancoast tumors

lung cancer and, Nov. 727-728 survival data in, Nov. 728

Pancreas

autotransplantation in diabetes, Sept. 589–590

CT showing cavity near head of, Oct. 629

gastric ulcer adherent to, Dec. 780

injuries of, Apr. 254-256

toxicity and chemotherapy of cancer, Oct. 627–629

transplantation in diabetes, Sept. 585–589

Pancreatitis: and benign biliary stricture, Jan. 57-58 Paralytic ileus: complicating chemotherapy of cancer, Oct. 623–624

Parietal cell: and gastric ulcer, Dec.

Pelvic fracture, Apr. 261-263

classification, Apr. 261 management, Apr. 262

Pelvic injuries: compound, Apr.

Penile blood flow: in diabetes, Sept. 555

Periampullary carcinoma, May 303–306

Peritoneovenous shunting: for malignant ascites, and metastases, Mar. 190

Peutz-Jeghers syndrome, May 288–289

Plantar abscess: in diabetes, Sept. 568

Pneumonia: in diabetes, Sept. 563–564

Pneumothorax

closed, Apr. 234-236

open, Apr. 227-229

tension, Apr. 234-236

Polyp(s)

colon. May 296-303

small intestine involvement in, May 300-302

discrete, in colon cancer syndrome, May 294-296

duodenal, in Gardner's syndrome, May 305

hamartomatous, of ileum in Cronkhite-Canada syndrome, May 287

hyperplastic, May 277

unclassified, May 275-276 intestinal, benign, histologic clas-

sification, May 276 juvenile, May 280

neoplastic, May 280–283

rectal, in Gardner's syndrome,

May 297

retention, May 280

types of, May 275 Polyposis, May 275–340

bony tumors and, May 310-312

Polyposis (cont.) coli. May 306 Quality of life: after urinary diverbirth incidence, May 293 sion. July 460 ileoproctostomy for, follow-up, May 318 familial. May 296-303 R gastric, May 302-303 Radiography gastrointestinal of biliary stricture, benign, Jan. classification. May 284 syndromes, May 283-284 interpretation of Jan. 22 hamartomatous, May 287-288 hereditary, May 287-315 of biliary stricture, malignant, inflammatory, May 276-277 Feb. 81 gastric ulcer intestinal, syndromes of, May 275-340 type I. Dec. 776 juvenile, May 287-288 type II. Dec. 777 neoplastic, May 290-294 Radiotherapy of bile duct tumors, Feb. 112-115 distribution, May 293 brachyradiotherapy, Oct. 664 historical review, May 290-292 chemoradiotherapy and wound ileoproctostomy for, rectal canhealing, Oct. 659-663 cer after, May 316 incidence, May 292-293 in lung cancer inheritance, May 293-294 non-small-cell (see Lung cancer. non-small-cell. radiothernonhereditary, May 284-287 perspective, May 328-329 small-cell, Nov. 738 research, May 324-328 for perianal inflammatory lesions soft tissue tumors. May 307-310 in leukemia, Oct. 626 treatment, May 315-321 Reconstruction: of biliary-enteric nonoperative, May 322 Portal hypertension: and biliary continuity in bile duct tumors. Feb. 94-97 stricture, Jan. 44-46 Portal vein Rectum bifurcation excision, with liver recancer after ileoproctostomy for neoplastic polyposis, May section, Feb. 101-103 right branch in resection of bile 316 duct tumors, Feb. 100-101 carcinoma (see Carcinoma, colostenosis, Feb. 86 Postcholecystectomy injuries (see complications in chemotherapy of cancer, Oct. 624-627 Cholecystectomy, injuries) hyperplasia, nodular lymphoid, Pseudopolyp: of ulcerative colitis, May 279 May 278 Pylorectomy, Dec. 770 polyps in Gardner's syndrome, Pyloric gastric ulcer May 297 Resuscitation: after burns, June barium study of type III, Dec. 347-349 778 channel, type III, Dec. 792 Retroperitoneal fibrosis, May 309 Round ligament approach: to bile Pyloroplasty: with vagotomy for gasduct tumors. Feb. 109-112 tric ulcer, Dec. 799-801 Pylorus sparing gastrectomy: in gas-Rupture

tric ulcer. Dec. 807-810

of aorta, contained, Apr. 246, 248

of diaphragm, Apr. 252 of tracheobronchial tree, Apr. 239–241 Rydygier, Ludwik, Dec. 770

s

Sato, T., Dec. 808 Sclerosing (see Cholangitis, sclerosing)

Sepsis: suspected in chemotherapy, effect of catheter exchange on catheter removal in, Oct. 655

Septic thrombophlebitis: and skin infections, Oct. 657–659

Shotgun blast with small bowel injury, Apr. 257 of torso, Apr. 228

Shunt

in carotid endarterectomy, avoidance in difficult neck, Aug. 520–521

late development of EEG changes necessitating, Aug. 522

malfunctioning, EEG changes reflecting, Aug. 521–522

Shunting: peritoneovenous, in malignant ascites, and metastases, Mar. 190

Sigmoid conduit diversion, July 419–424

bowel preparation in, July 419-420

operative technique, July 420–424 sigmoid segment isolation, July 421

stoma creation for, July 424 Skin

infections

in diabetes, Sept. 556–559 septic thrombophlebitis and, Oct. 657–659

in urinary diversion, July 407 Soft tissue infections: in diabetes, Sept. 556–559

Spleen: injuries of, Apr. 250–251 Splenoportography: in stenosis of portal vein, Feb. 86

Stenosis: of portal vein, Feb. 86

Stoma

construction with protruding "nipple," July 417

for ileal conduit diversion, preparation of, July 415–418

in ileal loop diversion, correct placement, July 410

loop ileocutaneous, Turnbull's method for, July 416

for sigmoid conduit diversion, July 424

Stomach (see Gastric, Gastrointestinal)

Subclavian artery: false aneurysm of, Apr. 245

T

Tension pneumothorax, Apr. 234–236

Thermal injury (see Burns) Thigh: desmoid tumors of, May 309 Thrombophlebitis: septic, and skin

infections Oct. 657–659 Tibial exostosis: in Gardner's syndrome, May 311

Toe: big, ulcer of, Sept. 578

Tomography, computed of cholangiocarcinoma, Jan. 11 of kidney injury, Apr. 260

of liver in intraparenchymal injury, Apr. 253

of lung contusion, Apr. 241, 242 of pancreas, showing large cavity near head. Oct. 629

Torso

coronal zones, Apr. 217 sagittal zones, Apr. 216 shotgun blast of, Apr. 228 trauma, Apr. 215–265

approaches to, general, Apr. 222–227

in motor vehicle accidents, incidence, Apr. 220 penetrating injuries, Apr. 219 relation of distance fallen to velocity at impact, Apr. 221

Foxicity

pancreatic, in chemotherapy of cancer, Oct. 627–629 Toxicity (cont.) renal, after chemotherapy of cancer, Oct. 646-647 Tracheobronchial tree: rupture, Apr. 239-241 Tracheostomy, Apr. 232 Transplantation (see Diabetes mellitus, transplantation) Trauma abdominal, causing biliary injury, Jan. 54-55 of genitalia, Apr. 258-259 torso (see Torso, trauma) T-tube: end-to-end anastomosis over, for biliary duct injury, Jan. 30 Tumors bony, and polyposis, May 310-312 cell(s) apy, Mar. 160-163

bile duct (see Bile duct tumors) heterogeneity, and chemotherhuman, metastatic propensity (in nude mice), Mar. 173-175 metastatic behavior of, Mar. 174-175 metastatic propensity in nude mice. Mar. 173-174 desmoid of thigh, May 309 treatment, May 322-324 doubling time, Mar. 186-187 fibrous, in Gardner's syndrome, May 309 heterogenous populations, instability of, Mar. 154-156 nude mouse as recipient for, Mar. 171-173

velopment of (in rat), Mar. 167–168 Pancoast (see Pancoast tumors) soft tissue, and polyposis, May 307–310 Turcot's syndrome, May 296–303

organ microenvironment in de-

Turnbull's method: for loop ileocutaneous stoma, July 416 Typhlitis: complicating chemotherapy of cancer, Oct. 632–633 Ulcer after adriamycin infiltration. Oct.

658
of big toe, Sept. 578
of Cruveilhier, Dec. 769
duodenal, and benign biliary
stricture, Jan. 56
gastric (see Gastric ulcer)
of bed, powerpathic, Sept. 569

gastric (see Gastric ulcer)
of heel, neuropathic, Sept. 569
mal perforans, and diabetes, Sept.
567

Ulcerative colitis: pseudopolyp of, May 278 Ultrasound

of cholangiocarcinoma, hilar, Feb.

Doppler, in cerebral blood flow measurement, Aug. 499–500 Ureterocecocutaneous ileostomy, July 433–438

Ureterocolonic anastomosis, July 423

Ureteroileal anastomosis, July 414 Ureteroileal diversion (see Ileal reservoir)

Ureterointestinal diversion: complications of, July 425–431 Ureterojejunal cutaneous diversion, July 418–419

Ureterosigmoid anastomosis: submucosal tunnels for, July 422 Ureterosigmoidostomy, July 431–432

Urinary diversion, July 407–471 colon for, transverse, July 424–425 continent, July 431 cutaneous, July 407 future direction, July 460–464

ileocecal, July 424, 426–427 quality of life after, July 460 ureteroileal (see Ileal reservoir) ureterointestinal, complications, July 425–431

ureterojejunal cutaneous, July 418–419

Urinary tract infections in diabetes, Sept. 561–562 injuries, Apr. 259–260

V

Vagotomy, Dec. 774 with drainage for gastric ulcer. Dec. 801 gastric (see Gastric vagotomy) with gastric resection, distal, Dec. 791-799 parietal cell, Dec. 803 truncal, with pyloroplasty for gastric ulcer, Dec. 799-801 Vein access for chemotherapy (see Chemotherapy of cancer, venous access) central (see Central venous catheportal (see Portal vein) Ventilatory function, Apr. 234 Vessels access for hemodialysis in diabe-

tes, Sept. 554-555

anatomy in cerebral blood flow, function and ischemic injury, Aug. 485–486 cerebral, disease in diabetes, Sept. 553–554 complications in diabetes, Sept. 546–555 great, injuries to, Apr. 244–247 injuries, Apr. 263–264 peripheral, disease complicating diabetes, Sept. 547–552

W

Weight "apparent," of organs in violent impact, Apr. 220 Wound healing: and chemoradiotherapy, Oct. 659–663 Wounding agents: to torso, Apr. 217–222